Lynparza Long-Term Responders Likely to have Deficient DNA Repair

Lynparza Long-Term Responders Likely to have Deficient DNA Repair
Long-term, progression-free survival in women with ovarian cancer treated with Lynparza (olaparib) is likely linked to deficient DNA repair mechanisms, particularly those caused by mutations in the BRCA genes. In addition to that finding, the study, “Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization,” showed that patients who had

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , , .

Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.

Leave a Comment

Your email address will not be published. Required fields are marked *